Result : 264

Living with… Kawasaki disease

 Alexandre Belot, Raphaël Darbon. June 2025, page 87

Neurofibromatosis type 1: recent advances

Neurofibromatosis type 1 (NF1) has been the subject of extensive research over the past decade, conducted by both French and international research groups. This work has led to significant...
 Laura Fertitta, Pierre Wolkenstein. June 2025, page 83

Chronic lymphocytic leukaemia

 Carolyne Croizier, Romain Guièze, Olivier Tournilhac. June 2025, page 91

From vaccination to smallpox eradication

Patrick Berche. June 2025, page 98

Management of neuropathic pain: Don’t lose hope!

Neuropathic pain represents a major challenge in the diagnosis and initiation of treatment. This article provides an overview of its definition, epidemiology, and common etiologies. Current...
 Emmanuel Nolot, Xavier Moisset, Nadine Attal. November 2025, page 12

Press review

 Francois Mallordy. November 2025, page 20

Special features of ANCA-associated vasculitides

Necrotizing vasculitis associated to antineutrophil cytoplasmic antibodies (ANCA) are one of the subgroups of vasculitis affecting small-sized vessels. Fibrinoid necrosis of the vascular wall is...
 Loïc Guillevin. November 2025, page 27

Epidemiology and risk factors of ANCAassociated vasculitides

ANCA-associated vasculitides (AAV) are a group of small-vessel vasculitides including microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with...
 Lucas Pacoureau, Maxime Beydon, Benjamin Terrier, Yann Nguyen. November 2025, page 34

Recent developments in the treatment of ANCA-associated vasculitides

The treatment of antineutrophil cytoplasm antibody-associated (ANCA) vasculitis is based on induction therapy to achieve remission, followed by maintenance therapy to prevent relapse. Management...
 Xavier Puéchal. November 2025, page 43

Towards more targeted therapies in the treatment of ANCA-associated vasculitides

The treatment of ANCA-associated vasculitides (AAV) is based on therapeutic strategies that achieve remission and significantly reduce the risk of relapse in most cases over the medium term....
 Alexandre Karras. November 2025, page 49

ANCA-associated vasculitides: 10 key messages

 Benjamin Terrier. November 2025, page 54

Functional neurological disorders

Functional Neurological Disorders (FND) are symptoms associated with dysfunctions in brain networks, often triggered by physical and/or psychological traumatic factors in vulnerable individuals....
 Béatrice Garcin. November 2025, page 60

Living with… the burden of obesity

 David Nocca. November 2025, page 65

Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?

Psychedelics, long marginalized, are now gaining renewed interest in psychiatry for their therapeutic potential. Substances
like psilocybin, LSD, and MDMA are being studied for treating...
 Michel Sabé, Federico Seragnoli, Louise Penzenstadler, Gabriel Thorens. November 2025, page 69